Introduction: Hyper-IgE Syndrome (HIES) is a rare inborn error of immunity (IEI) characterized by a constellation of symptoms related to susceptibility to Staphylococcal skin and pulmonary infections, eczema, raised serum IgE (>2,000 IU/ml), craniofacial anomalies, and recurrent bone fractures. Data on HIES from the Indian subcontinent is scarce and restricted to small case series and case reports. This is the first compilation of national data on HIES. Materials and Methods: A total 103 cases clinically diagnosed and treated as HIES were analyzed from nine centers. Cases with clinical and/or molecular diagnosis of DOCK8 deficiency were not included. Patients were divided into two groups: group I for whom a heterozygous rare variant of STAT3 was identified, and group II, with clinical features similar to those of AD STAT3 deficiency, but without any genetic diagnosis. Results: Genetic diagnosis was available in 27 patients (26.2%) and all harbored rare variants in the STAT3 gene. Majority of these STAT3 HIES patients presented with recurrent skin abscesses (77.7%) or pneumonia (62.9%) or both (59.2%). Other features included eczema (37%), candidiasis (55.5%), facial dysmorphism (55.5%), recurrent fractures (11.1%), and retained primary teeth (7.4%). Mycobacterial infections were seen in a significant 18.5%. Mortality was seen in three subjects (11.1%). A similar trend in the clinical presentation was observed when all the 103 patients were analyzed together. Twenty percent of patients without a rare variant in the STAT3 gene had an NIH score of ≥40, whereas, 51.9% of STAT3 HIES subjects had scores below the cut off of ≥40. TH17 cell numbers were low in 10/11 (90.9%) STAT3 HIES tested. Rare variants observed were 8 in exon 21; 8 in exon 13; 3 in exon 10; 2 in exon 15, and one each in exon 6, 16, 17, 19, 22, and splice site downstream of exon 12. Seven variants were novel and included F174S, N567D, L404Sfs*8, G419 =, M329K, T714I, R518X, and a splice site variant downstream of exon 12. Conclusions: The report includes seven novel STAT3 variants, including a rare linker domain nonsense variant and a CC domain variant. Mycobacterial diseases were more frequent, compared to western literature.
Introduction: Hyper-IgE Syndrome (HIES) is a rare inborn error of immunity (IEI) characterized by a constellation of symptoms related to susceptibility to Staphylococcal skin and pulmonary infections, eczema, raised serum IgE (>2,000 IU/ml), craniofacial anomalies, and recurrent bone fractures. Data on HIES from the Indian subcontinent is scarce and restricted to small case series and case reports. This is the first compilation of national data on HIES. Materials and Methods: A total 103 cases clinically diagnosed and treated as HIES were analyzed from nine centers. Cases with clinical and/or molecular diagnosis of DOCK8 deficiency were not included. Patients were divided into two groups: group I for whom a heterozygous rare variant of STAT3 was identified, and group II, with clinical features similar to those of AD STAT3 deficiency, but without any genetic diagnosis. Results: Genetic diagnosis was available in 27 patients (26.2%) and all harbored rare variants in the STAT3 gene. Majority of these STAT3HIESpatients presented with recurrent skin abscesses (77.7%) or pneumonia (62.9%) or both (59.2%). Other features included eczema (37%), candidiasis (55.5%), facial dysmorphism (55.5%), recurrent fractures (11.1%), and retained primary teeth (7.4%). Mycobacterial infections were seen in a significant 18.5%. Mortality was seen in three subjects (11.1%). A similar trend in the clinical presentation was observed when all the 103 patients were analyzed together. Twenty percent of patients without a rare variant in the STAT3 gene had an NIH score of ≥40, whereas, 51.9% of STAT3HIES subjects had scores below the cut off of ≥40. TH17 cell numbers were low in 10/11 (90.9%) STAT3HIES tested. Rare variants observed were 8 in exon 21; 8 in exon 13; 3 in exon 10; 2 in exon 15, and one each in exon 6, 16, 17, 19, 22, and splice site downstream of exon 12. Seven variants were novel and included F174S, N567D, L404Sfs*8, G419 =, M329K, T714I, R518X, and a splice site variant downstream of exon 12. Conclusions: The report includes seven novel STAT3 variants, including a rare linker domain nonsense variant and a CC domain variant. Mycobacterial diseases were more frequent, compared to western literature.
Authors: Yael Gernez; Alexandra F Freeman; Steven M Holland; Elizabeth Garabedian; Niraj C Patel; Jennifer M Puck; Kathleen E Sullivan; Javeed Akhter; Elizabeth Secord; Karin Chen; Rebecca Buckley; Elie Haddad; Hans D Ochs; Ramsay Fuleihan; John Routes; Mica Muskat; Patricia Lugar; Julien Mancini; Charlotte Cunningham-Rundles Journal: J Allergy Clin Immunol Pract Date: 2017-09-19
Authors: Jinbo Yang; Xudong Liao; Mukesh K Agarwal; Laura Barnes; Philip E Auron; George R Stark Journal: Genes Dev Date: 2007-05-17 Impact factor: 11.361
Authors: Tobias Schwerd; Stephen R F Twigg; Dominik Aschenbrenner; Santiago Manrique; Kerry A Miller; Indira B Taylor; Melania Capitani; Simon J McGowan; Elizabeth Sweeney; Astrid Weber; Liye Chen; Paul Bowness; Andrew Riordan; Andrew Cant; Alexandra F Freeman; Joshua D Milner; Steven M Holland; Natalie Frede; Miryam Müller; Dirk Schmidt-Arras; Bodo Grimbacher; Steven A Wall; E Yvonne Jones; Andrew O M Wilkie; Holm H Uhlig Journal: J Exp Med Date: 2017-07-26 Impact factor: 14.307
Authors: Sameer Bahal; Maha E Houssen; Ania Manson; Lorena Lorenzo; Mark A Russell; Noel G Morgan; Fariba Tahami; Sofia Grigoriadou Journal: Case Reports Immunol Date: 2019-10-13
Authors: Tala Shahin; Dominik Aschenbrenner; Deniz Cagdas; Sevgi Köstel Bal; Cecilia Domínguez Conde; Wojciech Garncarz; David Medgyesi; Tobias Schwerd; Betül Karaatmaca; Pınar Gur Cetinkaya; Saliha Esenboga; Stephen R F Twigg; Andrew Cant; Andrew O M Wilkie; Ilhan Tezcan; Holm H Uhlig; Kaan Boztug Journal: Haematologica Date: 2018-10-11 Impact factor: 9.941
Authors: Jun Lan; Yi Zhang; Min Song; Shan Cai; Hong Luo; Ruoyun OuYang; Pan Yang; Xiaoliu Shi; Yingjiao Long; Yan Chen Journal: Front Med (Lausanne) Date: 2022-05-04